NovoSeven® RT Coagulation Factor VIIa (Recombinant) logo.
NovoSeven® RT is indicated for congenital hemophilia A or B with inhibitors, congenital Factor VII deficiency, Glanzmann’s thrombasthenia with refractoriness to platelets, and acquired hemophilia.
Hi [Name],
We hope you’re well. Thanks again for your participation in the Novo Nordisk Consumer Council on [date].
For over 30 years, we’ve been here for the hemophilia B with inhibitors community. This experience keeps us focused on providing reliable treatment that fits your lifestyle. Along with fast bleed control, NovoSeven® RT offers the benefits of quick administration and easy storage.
Trusted bleed control. Experience fast bleed control in even the most life-threatening bleeds.a
Lower volumes mean fast infusion. Because it’s a low-volume treatment, NovoSeven® RT takes 2-5 minutes to infuse.b
Big bleed control for little ones. Trust NovoSeven® RT to safely and effectively treat your child.
Dosing designed with you in mind. NovoSeven® RT is available in 4 vial sizes.
We’d love to hear from you—please reach out to me directly with any questions or needs. I can also connect you with your local Hemophilia Community Liaison (HCL) if you’d prefer. They can provide 1-on-1 support for life with inhibitors and help you build community in your neck of the woods.
aIn compassionate use situations including surgery, central nervous system hemorrhages, severe intra-abdominal bleeding, and other life-threatening bleeding episodes.
bAdminister as a slow bolus injection over 2-5 minutes, depending on dose administered.
Selected Important Safety Information
What is the most important information I should know about NovoSeven® RT?
NovoSeven® RT may cause serious side effects, including:
  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT
Please click here or scroll below for additional Important Safety Information.
Hope to hear from you soon,
Michelle Jimenez
Associate Director, Patient Marketing
BioPharmaceuticals
Novo Nordisk Inc.
609-987-4879 (direct)
609-578-9985 (mobile)
What is NovoSeven® RT?
NovoSeven® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for:
  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with a decreased or absent response to platelet transfusions
  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia
Important Safety Information (cont’d)
  • You should not use NovoSeven® RT if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reactions (anaphylaxis) to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. Signs of allergic reaction include shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness
What should I tell my healthcare provider before using NovoSeven® RT?
  • Tell your healthcare provider if you have any of the following, as these may increase your risk of blood clots:
  ◦ congenital hemophilia and are also receiving treatment with aPCCs (activated prothrombin complex concentrates)
  ◦ are an older patient particularly with acquired hemophilia and receiving other agents to stop bleeding
  ◦ history of heart or blood vessel diseases
 
  • Tell your healthcare provider and pharmacist about all the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies
What are the possible side effects of NovoSeven® RT?
  • The most common and serious side effects are blood clots
  • Tell your healthcare provider about any side effects that bother you or do not go away, and seek medical help right away if you have signs of a blood clot or allergic reaction
Please click here for Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.

MixPro® and NovoSeven® is a registered trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
© 2020 Novo Nordisk  All rights reserved.  US20NSVN00062  October 2020
  Novo Nordisk logo.